Tenon Medical, Inc. Announces Closing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Tenon Medical, Inc. Announces Closing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-281531) previously filed with the Securities and Exchange Commission ("SEC") which was declared effective on September 12, 2024. LOS GATOS, CA / ACCESSWIRE / September 17, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced the closing of its previously announced "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of 1,222,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,222,850 shares of common stock at a combined offering price of $3.68 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the "Offering").
洛斯加託斯，加州/ACCESSWIRE/2024年9月17日/第Tenon Medical公司（納斯達克股票代碼：TNON）（"Tenon"或「公司」），一家公司正在改變治療患有特定骶髂關節（SI關節）疾病的患者的關懷，今天宣佈其先前宣佈的與專注於醫療保健的機構投資者進行「合理盡力」的公開發行已經結束，該發行爲購買和出售12.22萬股普通股（或相當於此的預先資助認股權）和認股權證，以3.68美元每股和附帶認股權證的組合發行價格，按納斯達克規則以市場價格定價（"發行"）。
The Company received aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses. The warrants have an exercise price of $3.55 per share, are exercisable immediately and will expire five years from the issuance date.
公司收到了約450萬美元的總收入，扣除承銷代理費和其他發行費用。認股證的行權價爲每股3.55美元，可立即行使，並將在發行日起五年後到期。
A.G.P./Alliance Global Partners acted as the sole placement agent for the Offering.
A.G.P./Alliance Global Partners擔任了該發行的唯一配售代理商。
The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-281531) previously filed with the Securities and Exchange Commission ("SEC") which was declared effective on September 12, 2024.
上述證券是根據公司先前與美國證券交易委員會（"SEC"）申報生效於2024年9月12日的Form S-1註冊聲明（文件號333-281531）進行發行的。
This Offering was made only by means of a prospectus forming part of the effective registration statement. Copies of the preliminary prospectus and the final prospectus, relating to the Offering may be obtained on the SEC's website located at http://www.sec.gov.
本次發行僅通過構成有效註冊聲明一部分的招股說明書進行。有關發行的初步招股說明書和最終招股說明書的副本可在位於http://www.sec.gov的SEC網站上獲取。
Electronic copies of the final prospectus relating to the Offering may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
有關發行的最終招股說明書的電子副本可從全球合作伙伴A.G.P./Alliance Global Partners，位於紐約麥迪遜大道590號28樓，郵政編碼10022，電話（212）624-2060，或電子郵件prospectus@allianceg.com獲取。
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Tonix Pharmaceuticals Holding Corp.*，是一家完全整合的生物製藥公司，致力於發展富有創新性的治療和預防潛在疾病的製劑。公司正在研發針對纖維肌痛患者的產品TNX-102 SL，已經完成了兩項具有統計學意義的3期研究。TNX-102 SL也正在被開發用於治療急性壓力反應以及類纖維肌痛的長期COVID。Tonix的神經系統藥物組合包括TNX-1300（可卡因酯酶），這是一種用於治療可卡因中毒、被授予「突破性療法」稱號的生物製品。Tonix的免疫學研發組合包括生物製品，用於治療器官移植排斥、自身免疫和癌症，包括TNX-1500，這是一種人源單克隆抗體，靶向CD40L（CD40L或CD154）用於預防異體移植器官排斥並用於治療自身免疫性疾病。Tonix在罕見疾病和傳染病領域的正在研發中的產品。商業子公司Tonix Medicines市場上銷售Zembrace SymTouch（舒馬曲坦注射液）3毫克和Tosymra（舒馬曲坦鼻噴劑）10毫克，用於成年急性偏頭疼的治療。
IR Contact:
IR聯繫方式：
Shannon Devine: 203-741-8811
MZ North America
tenon@mzgroup.us
Shannon Devine: 203-741-8811
MZ北美
tenon@mzgroup.us
SOURCE: Tenon Medical, Inc.
來源：Tenon Medical, Inc。
譯文內容由第三人軟體翻譯。